Cloud-native healthcare technology company SOPHiA GENETICS (NASDAQ:SOPH) said on Friday that it has entered into a strategic collaboration with Belgian hospital Jessa Ziekenhuis to enhance genomic testing and oncology research across the country.

Jessa Ziekenhuis, which serves a population of more than 530,000 and processes over 3,000 oncology DNA and RNA samples annually, will implement the SOPHiA DDM platform to standardise its next-generation sequencing workflows. The integration covers universal library preparation, automated protocols, and harmonised operations in line with national ComPerMed guidelines.

The hospital will adopt six SOPHiA GENETICS applications supporting solid tumour testing, hematologic malignancies, and liquid biopsy analysis. The solution combines cloud-based capabilities, embedded automation, and advanced analytics fully integrated with Jessa Ziekenhuis's Laboratory Information Management System.

By unifying its pathology workflows, Jessa Ziekenhuis expects to reduce hands-on time by up to 50%, cut costs by as much as 25%, and accelerate turnaround times. The initiative is also intended to improve scalability and resource efficiency in sequencing operations.

The partnership extends beyond Jessa Ziekenhuis through the Bridge Consortium, a joint initiative with AZ Delta regional hospital in Roeselare. Leveraging SOPHiA DDM Dispatch, both hospitals will share a NovaSeq sequencer, optimising sequencing capacity and strengthening knowledge exchange.